Stephens & Co. Maintains Overweight on Amrize, Lowers Price Target to $54
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Stephens & Co. analyst Trey Grooms maintains Amrize (NYSE:AMRZ) with a Overweight and lowers the price target from $65 to $54.
Stephens & Co. analyst Trey Grooms maintains Amrize (NYSE:AMRZ) with a Overweight and lowers the price target from $65 to $54.